{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:53:38Z","timestamp":1788778418638,"version":"build-2803163510"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022485016"],"award-info":[{"award-number":["2022485016"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.cellsig.2025.111703","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:22:04Z","timestamp":1741000924000},"page":"111703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Histone modification inhibitors: An emerging frontier in thyroid Cancer therapy"],"prefix":"10.1016","volume":"131","author":[{"given":"Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12040712","article-title":"Molecular pathology of thyroid tumors: essential points to comprehend regarding the latest WHO Classification [J]","volume":"12","author":"Chiba","year":"2024","journal-title":"Biomedicines"},{"issue":"21","key":"10.1016\/j.cellsig.2025.111703_bb0010","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1097\/CM9.0000000000003284","article-title":"Global burden of thyroid cancer in 2022: incidence and mortality estimates from GLOBOCAN [J]","volume":"137","author":"Lyu","year":"2024","journal-title":"Chin. Med. J."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101678","article-title":"Anaplastic thyroid cancer: an update [J]","volume":"37","author":"Rao","year":"2023","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cellsig.2025.111703_bb0025","article-title":"Optical diagnostic imaging and therapy for thyroid cancer [J]","volume":"17","author":"Shao","year":"2022","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.cellsig.2025.111703_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2021.145998","article-title":"Epigenetic regulation of gene expression in response to environmental exposures: from bench to model [J]","volume":"776","author":"Li","year":"2021","journal-title":"Sci. Total Environ."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-022-01078-9","article-title":"The role of histone modifications: from neurodevelopment to neurodiseases [J]","volume":"7","author":"Park","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cellsig.2025.111703_bb0040","doi-asserted-by":"crossref","DOI":"10.1007\/s12038-020-00099-2","article-title":"Evaluation of post-translational modifications in histone proteins: a review on histone modification defects in developmental and neurological disorders [J]","volume":"45","author":"Ramazi","year":"2020","journal-title":"J. Biosci."},{"issue":"6498","key":"10.1016\/j.cellsig.2025.111703_bb0045","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.aaz1646","article-title":"Single-molecule regulatory architectures captured by chromatin fiber sequencing [J]","volume":"368","author":"Stergachis","year":"2020","journal-title":"Science (New York, N.Y.)"},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040559","article-title":"Epigenetic targets and their inhibitors in thyroid cancer treatment [J]","volume":"16","author":"Zhang","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s44161-024-00460-w","article-title":"Histone H1.0 couples cellular mechanical behaviors to chromatin structure [J]","volume":"3","author":"Hu","year":"2024","journal-title":"Nat. Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tig.2021.10.003","article-title":"The H2A Z-nucleosome code in mammals: emerging functions [J]","volume":"38","author":"Colino-Sanguino","year":"2022","journal-title":"Trends Genet."},{"issue":"7818","key":"10.1016\/j.cellsig.2025.111703_bb0065","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41586-020-2533-0","article-title":"Histone H3.3 phosphorylation amplifies stimulation-induced transcription [J]","volume":"583","author":"Armache","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cellsig.2025.111703_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108818","article-title":"Phosphorylation state of the histone variant H2A.X controls human stem and progenitor cell fate decisions [J]","volume":"34","author":"Orlando","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellsig.2025.111703_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2024.103711","article-title":"PARticular MARks: histone ADP-ribosylation and the DNA damage response [J]","volume":"140","author":"\u00d6zdemir","year":"2024","journal-title":"DNA Repair"},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104094","article-title":"Targeting histone deacetylases: emerging applications beyond cancer [J]","volume":"29","author":"Raouf","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188837","article-title":"Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer [J]","volume":"1878","author":"He","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"11","key":"10.1016\/j.cellsig.2025.111703_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2023.04.017","article-title":"LKB1 controls inflammatory potential through CRTC2-dependent histone acetylation [J]","volume":"83","author":"Compton","year":"2023","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.cellsig.2025.111703_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2021.03.008","article-title":"Enhancers are activated by p300\/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release [J]","volume":"81","author":"Narita","year":"2021","journal-title":"Mol. Cell"},{"issue":"16","key":"10.1016\/j.cellsig.2025.111703_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2023.06.032","article-title":"Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation [J]","volume":"83","author":"Zheng","year":"2023","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1042\/EBC20180061","article-title":"Acetylation & co: an expanding repertoire of histone acylations regulates chromatin and transcription [J]","volume":"63","author":"Barnes","year":"2019","journal-title":"Essays Biochem."},{"key":"10.1016\/j.cellsig.2025.111703_bb0110","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1038\/ncomms8048","article-title":"Transcriptional activation by the thyroid hormone receptor through ligand-dependent receptor recruitment and chromatin remodeling [J]","volume":"6","author":"Gr\u00f8ntved","year":"2015","journal-title":"Nat. Commun."},{"issue":"7405","key":"10.1016\/j.cellsig.2025.111703_bb0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature11043","article-title":"SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation [J]","volume":"487","author":"Barber","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2025.111703_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117936","article-title":"The Ras-ERK1\/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer [J]","volume":"256","author":"Li","year":"2020","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2011.06.182","article-title":"Levels of histone acetylation in thyroid tumors [J]","volume":"411","author":"Puppin","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2025.111703_bb0130","article-title":"Genome-wide histone H3K27 acetylation profiling identified genes correlated with prognosis in papillary thyroid carcinoma [J]","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008770","article-title":"Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone [J]","volume":"16","author":"Pr\u00e6stholm","year":"2020","journal-title":"PLoS Genet."},{"key":"10.1016\/j.cellsig.2025.111703_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108614","article-title":"Chemical inhibitors targeting histone methylation readers [J]","volume":"256","author":"Huang","year":"2024","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/cge.14181","article-title":"Disorders of histone methylation: molecular basis and clinical syndromes [J]","volume":"102","author":"Al Ojaimi","year":"2022","journal-title":"Clin. Genet."},{"key":"10.1016\/j.cellsig.2025.111703_bb0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mrrev.2017.09.003","article-title":"Histone methylation and the DNA damage response [J]","volume":"780","author":"Gong","year":"2019","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"issue":"12","key":"10.1016\/j.cellsig.2025.111703_bb0155","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.stemcr.2023.10.017","article-title":"DOT1L interaction partner AF10 controls patterning of H3K79 methylation and RNA polymerase II to maintain cell identity [J]","volume":"18","author":"Wille","year":"2023","journal-title":"Stem Cell Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0160","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1038\/s41467-023-43115-3","article-title":"Release of histone H3K4-reading transcription factors from chromosomes in mitosis is independent of adjacent H3 phosphorylation [J]","volume":"14","author":"Harris","year":"2023","journal-title":"Nat. Commun."},{"issue":"17\u201318","key":"10.1016\/j.cellsig.2025.111703_bb0165","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1101\/gad.350814.123","article-title":"Distinct accessory roles of Arabidopsis VEL proteins in polycomb silencing [J]","volume":"37","author":"Franco-Echevarr\u00eda","year":"2023","journal-title":"Genes Dev."},{"issue":"27","key":"10.1016\/j.cellsig.2025.111703_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk0793","article-title":"HP1 oligomerization compensates for low-affinity H3K9me recognition and provides a tunable mechanism for heterochromatin-specific localization [J]","volume":"8","author":"Biswas","year":"2022","journal-title":"Sci. Adv."},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2023.03.018","article-title":"PRC2.1- and PRC2.2-specific accessory proteins drive recruitment of different forms of canonical PRC1 [J]","volume":"83","author":"Glancy","year":"2023","journal-title":"Mol. Cell"},{"issue":"8021","key":"10.1016\/j.cellsig.2025.111703_bb0180","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41586-024-07640-5","article-title":"Targeting pericentric non-consecutive motifs for heterochromatin initiation [J]","volume":"631","author":"Ma","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2025.111703_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589929","article-title":"TERT-regulation and roles in cancer formation [J]","volume":"11","author":"Dratwa","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cellsig.2025.111703_bb0190","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1089\/thy.2020.0055","article-title":"Characterization of allele-specific regulation of telomerase reverse transcriptase in promoter mutant thyroid cancer cell lines [J]","volume":"30","author":"Mckelvey","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12935-024-03459-2","article-title":"TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer [J]","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/cen.14192","article-title":"Diagnostic significance of DNA methylation of PTEN and DAPK in thyroid tumors [J]","volume":"93","author":"Wei","year":"2020","journal-title":"Clin. Endocrinol."},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0205","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/2159-8290.CD-18-0083","article-title":"PTEN methylation by NSD2 controls cellular sensitivity to DNA damage [J]","volume":"9","author":"Zhang","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41419-024-06476-1","article-title":"SHMT2 promotes papillary thyroid cancer metastasis through epigenetic activation of AKT signaling [J]","volume":"15","author":"Sun","year":"2024","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.cellsig.2025.111703_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123807","article-title":"The RASSF1A tumor suppressor binds the RasGAP DAB2IP and modulates RAS activation in lung Cancer [J]","volume":"12","author":"Harrell Stewart","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cellsig.2025.111703_bb0220","doi-asserted-by":"crossref","unstructured":"Kunstman J W, Korah R, Healy J M, et al. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma [J]. Surgery, 2013, 154(6): 1255\u201361; discussion 61\u20132.","DOI":"10.1016\/j.surg.2013.06.025"},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184892","article-title":"Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer [J]","volume":"12","author":"Khatami","year":"2017","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.cellsig.2025.111703_bb0230","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4161\/epi.20524","article-title":"Correlation between BRAF mutation and promoter methylation of TIMP3, RAR\u03b22, and RASSF1A in thyroid cancer [J]","volume":"7","author":"Brait","year":"2012","journal-title":"Epigenetics"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0235","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12957-023-03240-1","article-title":"Role of hypermethylated SLC5A8 in follicular thyroid cancer diagnosis and prognosis prediction [J]","volume":"21","author":"Yang","year":"2023","journal-title":"World J. Surg. Oncol."},{"issue":"10","key":"10.1016\/j.cellsig.2025.111703_bb0240","doi-asserted-by":"crossref","first-page":"6954","DOI":"10.1002\/jcp.29591","article-title":"Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF(V600E) mutation as biomarkers for papillary thyroid carcinoma [J]","volume":"235","author":"Khatami","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.cellsig.2025.111703_bb0245","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fendo.2012.00040","article-title":"Epigenetics modifications and therapeutic prospects in human thyroid cancer [J]","volume":"3","author":"Catalano","year":"2012","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0250","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-313X.2012.05029.x","article-title":"Phosphorylation of histone H2A is associated with centromere function and maintenance in meiosis [J]","volume":"71","author":"Dong","year":"2012","journal-title":"Plant J."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0255","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1038\/s41467-023-40843-4","article-title":"Histone H3 serine-57 is a CHK1 substrate whose phosphorylation affects DNA repair [J]","volume":"14","author":"Parisis","year":"2023","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.cellsig.2025.111703_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2021.08.029","article-title":"SPT5 stabilizes RNA polymerase II, orchestrates transcription cycles, and maintains the enhancer landscape [J]","volume":"81","author":"Hu","year":"2021","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062484","article-title":"Evidence against a role for the JIL-1 kinase in H3S28 phosphorylation and 14-3-3 recruitment to active genes in Drosophila [J]","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0270","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13148-020-00941-2","article-title":"Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy [J]","volume":"12","author":"Komar","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.cellsig.2025.111703_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2024.124047","article-title":"Influence of different pH milieu on the structure and function of human Aurora kinase B protein (AURK-B): amalgamation of both spectroscopic and computational approach [J]","volume":"312","author":"Gupta","year":"2024","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"issue":"23","key":"10.1016\/j.cellsig.2025.111703_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.devcel.2023.10.002","article-title":"The anaphase-promoting complex controls a ubiquitination-phosphoprotein axis in chromatin during neurodevelopment [J]","volume":"58","author":"Ledvin","year":"2023","journal-title":"Dev. Cell"},{"issue":"40","key":"10.1016\/j.cellsig.2025.111703_bb0285","doi-asserted-by":"crossref","first-page":"14296","DOI":"10.1523\/JNEUROSCI.2890-11.2011","article-title":"Alterations of molecular and behavioral responses to cocaine by selective inhibition of Elk-1 phosphorylation [J]","volume":"31","author":"Besnard","year":"2011","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040604","article-title":"MSK-mediated phosphorylation of histone H3 Ser28 couples MAPK Signalling with early gene induction and cardiac hypertrophy [J]","volume":"11","author":"Robinson","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2025.111703_bb0295","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcancer.2017.04.016","article-title":"Defining the role of the RSK isoforms in cancer [J]","volume":"48","author":"Houles","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"18","key":"10.1016\/j.cellsig.2025.111703_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/cells13181546","article-title":"Targeting the p90RSK\/MDM2\/p53 pathway is effective in blocking tumors with oncogenic up-regulation of the MAPK pathway such as melanoma and lung cancer [J]","volume":"13","author":"Maietta","year":"2024","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.cellsig.2025.111703_bb0305","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nsmb.2310","article-title":"Phosphorylation of histone H3 Ser10 establishes a hierarchy for subsequent intramolecular modification events [J]","volume":"19","author":"Liokatis","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0310","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s44319-024-00107-8","article-title":"Identification of plants\u2019 functional counterpart of the metazoan mediator of DNA damage checkpoint 1 [J]","volume":"25","author":"Lorkovi\u0107","year":"2024","journal-title":"EMBO Rep."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0315","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2214\/AJR.19.22626","article-title":"Radioactive iodine therapy in differentiated thyroid cancer: 2020 update [J]","volume":"215","author":"Ciarallo","year":"2020","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0320","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1038\/s41467-022-35715-2","article-title":"Arabidopsis \u03b3-H2A.X-interacting protein participates in DNA damage response and safeguards chromatin stability [J]","volume":"13","author":"Fan","year":"2022","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.cellsig.2025.111703_bb0325","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1111\/jcmm.16676","article-title":"Histone succinylation and its function on the nucleosome [J]","volume":"25","author":"Liu","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0330","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/BCJ20180745","article-title":"Structural insights into the molecular mechanism underlying Sirt5-catalyzed desuccinylation of histone peptides [J]","volume":"476","author":"Hang","year":"2019","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0335","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/nar\/gkx053","article-title":"SIRT7-dependent deacetylation of CDK9 activates RNA polymerase II transcription [J]","volume":"45","author":"Blank","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cellsig.2025.111703_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2019.09.015","article-title":"KAT2A succinyltransferase activity-mediated 14-3-3\u03b6 upregulation promotes \u03b2-catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells [J]","volume":"469","author":"Tong","year":"2020","journal-title":"Cancer Lett."},{"issue":"7684","key":"10.1016\/j.cellsig.2025.111703_bb0345","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature25003","article-title":"KAT2A coupled with the \u03b1-KGDH complex acts as a histone H3 succinyltransferase [J]","volume":"552","author":"Wang","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/dgd.12645","article-title":"PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer [J]","volume":"62","author":"Lu","year":"2020","journal-title":"Develop. Growth Differ."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0355","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21883-0","article-title":"Investigation of in vitro histone H3 glycosylation using H3 tail peptides [J]","volume":"12","author":"Merx","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062980","article-title":"Epigenetic regulation of glycosylation in cancer and other diseases [J]","volume":"22","author":"Indellicato","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010455","article-title":"FUT8 alpha-(1,6)-fucosyltransferase in cancer [J]","volume":"22","author":"Bastian","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0370","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/abt\/tbad004","article-title":"Beyond antibody fucosylation: \u03b1-(1,6)-fucosyltransferase (Fut8) as a potential new therapeutic target for cancer immunotherapy [J]","volume":"6","author":"Mao","year":"2023","journal-title":"Antibody Therap."},{"issue":"11","key":"10.1016\/j.cellsig.2025.111703_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e31778","article-title":"C1GALT1 induces the carcinogenesis of thyroid cancer through regulation by miR-141-3p and GLUT1 [J]","volume":"10","author":"Huang","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0380","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41388-019-0975-3","article-title":"O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth [J]","volume":"39","author":"Singh","year":"2020","journal-title":"Oncogene"},{"issue":"30","key":"10.1016\/j.cellsig.2025.111703_bb0385","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1038\/s41388-021-01901-7","article-title":"OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP [J]","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"issue":"49","key":"10.1016\/j.cellsig.2025.111703_bb0390","article-title":"Arginine methylation of BRD4 by PRMT2\/4 governs transcription and DNA repair [J]. Science","volume":"8","author":"Liu","year":"2022","journal-title":"Advances"},{"issue":"14","key":"10.1016\/j.cellsig.2025.111703_bb0395","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1021\/jacs.3c14380","article-title":"Targeted protein O-GlcNAcylation using bifunctional small molecules [J]","volume":"146","author":"Ma","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0400","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.18632\/aging.102910","article-title":"ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma [J]","volume":"12","author":"He","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.cellsig.2025.111703_bb0405","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jconrel.2024.03.057","article-title":"Disrupting glycolysis and DNA repair in anaplastic thyroid cancer with nucleus-targeting platinum nanoclusters [J]","volume":"369","author":"Pan","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0410","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","article-title":"STAT5 promotes PD-L1 expression by facilitating histone acetylation to drive immunosuppression in acute myeloid leukemia [J]","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0415","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12964-020-00586-x","article-title":"Regulators of glucose uptake in thyroid cancer cell lines [J]","volume":"18","author":"Heydarzadeh","year":"2020","journal-title":"Cell Commun. Signal."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0420","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317695922","article-title":"Glycolysis-related protein expression in thyroid cancer [J]","volume":"39","author":"Nahm","year":"2017","journal-title":"Tumour Biol."},{"issue":"8","key":"10.1016\/j.cellsig.2025.111703_bb0425","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0344","article-title":"BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation [J]","volume":"30","author":"Wang","year":"2023","journal-title":"Endocr. Relat. Cancer"},{"issue":"13","key":"10.1016\/j.cellsig.2025.111703_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e34032","article-title":"Ubiquitin-modifying enzymes in thyroid cancer: mechanisms and functions [J]","volume":"10","author":"Xiong","year":"2024","journal-title":"Heliyon"},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0435","doi-asserted-by":"crossref","first-page":"10538","DOI":"10.1096\/fj.201900415R","article-title":"Two distinct E3 ligases, SCF(FBXL19) and HECW1, degrade thyroid transcription factor 1 in normal thyroid epithelial and follicular thyroid carcinoma cells, respectively [J]","volume":"33","author":"Liu","year":"2019","journal-title":"FASEB J."},{"issue":"7330","key":"10.1016\/j.cellsig.2025.111703_bb0440","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life [J]","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/genes10010067","article-title":"Writing histone monoubiquitination in human malignancy-the role of RING finger E3 ubiquitin ligases [J]","volume":"10","author":"Marsh","year":"2019","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0450","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.tibs.2020.11.005","article-title":"Chromatin regulation through ubiquitin and ubiquitin-like histone modifications [J]","volume":"46","author":"Vaughan","year":"2021","journal-title":"Trends Biochem. Sci."},{"issue":"17","key":"10.1016\/j.cellsig.2025.111703_bb0455","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1158\/0008-5472.CAN-11-1896","article-title":"Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B [J]","volume":"71","author":"Prenzel","year":"2011","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.cellsig.2025.111703_bb0460","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.humpath.2015.04.001","article-title":"Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma [J]","volume":"46","author":"Wang","year":"2015","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020165","article-title":"Developing targeted therapies that exploit aberrant histone ubiquitination in cancer [J]","volume":"8","author":"Jeusset","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2025.111703_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102649","article-title":"Diverse modes of regulating methyltransferase activity by histone ubiquitination [J]","volume":"82","author":"Fields","year":"2023","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"13","key":"10.1016\/j.cellsig.2025.111703_bb0475","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137459","article-title":"SAGA-dependent histone H2Bub1 deubiquitination is essential for cellular ubiquitin balance during embryonic development [J]","volume":"23","author":"El-Saafin","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2018.08.020","article-title":"Comprehensive mapping of histone modifications at DNA double-strand breaks deciphers repair pathway chromatin signatures [J]","volume":"72","author":"Clouaire","year":"2018","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.cellsig.2025.111703_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs [J]","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020454","article-title":"HDAC1 and HDAC2 double knockout triggers cell apoptosis in advanced thyroid cancer [J]","volume":"20","author":"Lin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0495","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00210-023-02674-4","article-title":"Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents [J]","volume":"397","author":"Wahi","year":"2024","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"21","key":"10.1016\/j.cellsig.2025.111703_bb0500","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy [J]","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.cellsig.2025.111703_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116127","article-title":"HDAC\/NAMPT dual inhibitors overcome initial drug resistance in p53-null leukemia cells [J]","volume":"266","author":"Yue","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0510","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.surg.2010.10.007","article-title":"Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors [J]","volume":"149","author":"Mitmaker","year":"2011","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.cellsig.2025.111703_bb0515","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1210\/jc.2010-1421","article-title":"Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target [J]","volume":"95","author":"Marlow","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.cellsig.2025.111703_bb0520","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/1078-0432.CCR-23-2043","article-title":"Combined vorinostat and chloroquine inhibit sodium-iodide symporter endocytosis and enhance radionuclide uptake in vivo [J]","volume":"30","author":"Read","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2025.111703_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112831","article-title":"Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment [J]","volume":"208","author":"Peng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"10.1016\/j.cellsig.2025.111703_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184700","article-title":"Vorinostat (SAHA) and breast cancer: an overview [J]","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0535","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomized, controlled phase 3 trial [J]","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.cellsig.2025.111703_bb0540","first-page":"859","article-title":"The discovery and development of romidepsin for the treatment of T-cell lymphoma [J]","volume":"12","author":"Smolewski","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"issue":"10","key":"10.1016\/j.cellsig.2025.111703_bb0545","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy [J]","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"12","key":"10.1016\/j.cellsig.2025.111703_bb0550","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium (PBTC-047) [J]","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro-oncology"},{"issue":"23","key":"10.1016\/j.cellsig.2025.111703_bb0555","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study [J]","volume":"33","author":"O\u2019connor","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0560","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2016.02.043","article-title":"Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - the SHELTER study [J]","volume":"65","author":"Bitzer","year":"2016","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041070","article-title":"Combination of resminostat with ruxolitinib exerts antitumor effects in the chick embryo chorioallantoic membrane model for cutaneous T cell lymphoma [J]","volume":"14","author":"Karagianni","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.cellsig.2025.111703_bb0570","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval [J]","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0575","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","article-title":"Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study [J]","volume":"3","author":"Garcia-Manero","year":"2019","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0580","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed\/refractory lymphoma [J]","volume":"22","author":"Evens","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0585","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-11-3165","article-title":"A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors [J]","volume":"18","author":"Banerji","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.cellsig.2025.111703_bb0590","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/1078-0432.CCR-14-2820","article-title":"A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma [J]","volume":"21","author":"Galloway","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0595","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1535-7163.MCT-12-1045","article-title":"Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion [J]","volume":"12","author":"Wang","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"19","key":"10.1016\/j.cellsig.2025.111703_bb0600","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-14-0570","article-title":"Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors [J]","volume":"20","author":"Shimizu","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0605","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA) [J]","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0610","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12967-023-04015-8","article-title":"Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner [J]","volume":"21","author":"Giordano","year":"2023","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0615","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020423","article-title":"Sodium butyrate induces CRC cell ferroptosis via the CD44\/SLC7A11 pathway and exhibits a synergistic therapeutic effect with erastin [J]","volume":"15","author":"Bian","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cellsig.2025.111703_bb0620","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.2147\/DDDT.S211665","article-title":"AR-42: a Pan-HDAC inhibitor with antitumor and antiangiogenic activities in esophageal squamous cell carcinoma [J]","volume":"13","author":"Zhu","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"8","key":"10.1016\/j.cellsig.2025.111703_bb0625","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1078-0432.CCR-20-3724","article-title":"Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition [J]","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.cellsig.2025.111703_bb0630","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis [J]","volume":"383","author":"Paganoni","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0635","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","article-title":"Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial [J]","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0640","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hon.3088","article-title":"Chidamide: targeting epigenetic regulation in the treatment of hematological malignancy [J]","volume":"41","author":"Cao","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0645","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","article-title":"Synergistic effect of HDAC inhibitor chidamide with cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia [J]","volume":"12","author":"Gu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0650","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China [J]","volume":"10","author":"Shi","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0655","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10495-017-1364-4","article-title":"Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine [J]","volume":"22","author":"Cosenza","year":"2017","journal-title":"Apoptosis"},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0660","first-page":"257","article-title":"Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer [J]","volume":"4","author":"Zeleke","year":"2023","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0665","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.critrevonc.2008.03.002","article-title":"The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer [J]","volume":"68","author":"Gridelli","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cellsig.2025.111703_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112431","article-title":"Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A [J]","volume":"145","author":"Lin","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0675","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/cncr.31817","article-title":"Mocetinostat for patients with previously treated, locally advanced\/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes [J]","volume":"125","author":"Grivas","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0680","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cllc.2023.01.013","article-title":"Mocetinostat in combination with Durvalumab for patients with advanced NSCLC: results from a phase I\/II study [J]","volume":"24","author":"Johnson","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"13","key":"10.1016\/j.cellsig.2025.111703_bb0685","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin\u2019s lymphoma: an open-label, single-arm, phase 2 trial [J]","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.cellsig.2025.111703_bb0690","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/ard-2022-223789","article-title":"Inhibition of KDM7A\/B histone demethylases restores H3K79 methylation and protects against osteoarthritis [J]","volume":"82","author":"Assi","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"23","key":"10.1016\/j.cellsig.2025.111703_bb0695","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.2174\/0929867330666230607124803","article-title":"An updated review on the significance of DNA and protein methyltransferases and De-methylases in human diseases: from molecular mechanism to novel therapeutic approaches [J]","volume":"31","author":"Ghanbari","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.cellsig.2025.111703_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115982","article-title":"Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: current progress and novel strategies [J]","volume":"264","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0705","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval [J]","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0710","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study [J]","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"issue":"7427","key":"10.1016\/j.cellsig.2025.111703_bb0715","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations [J]","volume":"492","author":"Mccabe","year":"2012","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.cellsig.2025.111703_bb0720","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of Zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors [J]","volume":"25","author":"Yap","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0725","doi-asserted-by":"crossref","first-page":"E962","DOI":"10.1210\/jc.2013-3147","article-title":"PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-deazaneplanocin a [J]","volume":"99","author":"Cui","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24097872","article-title":"Modulation of EZH2 activity induces an antitumoral effect and cell redifferentiation in anaplastic thyroid Cancer [J]","volume":"24","author":"De Mello","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellsig.2025.111703_bb0735","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64960","article-title":"Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia","volume":"10","author":"Richter","year":"2021","journal-title":"eLife"},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0740","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/febs.16605","article-title":"DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-\u03baB-HIF1\u03b1 axis [J]","volume":"290","author":"Neeli","year":"2023","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0745","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/leu.2012.327","article-title":"Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l [J]","volume":"27","author":"Chen","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.cellsig.2025.111703_bb0750","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial [J]","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellsig.2025.111703_bb0755","article-title":"EZH2 inhibitors suppress colorectal cancer by regulating macrophage polarization in the tumor microenvironment [J]","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0760","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.7150\/thno.83353","article-title":"Histone H3K27 methyltransferase EZH2 regulates apoptotic and inflammatory responses in sepsis-induced AKI [J]","volume":"13","author":"Li","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.cellsig.2025.111703_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115493","article-title":"Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo [J]","volume":"210","author":"Zhu","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cellsig.2025.111703_bb0770","article-title":"Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer [J]","volume":"6","author":"Song","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2025.111703_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104972","article-title":"Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic [J]","volume":"100","author":"Guo","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0780","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12935-014-0149-x","article-title":"EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells [J]","volume":"15","author":"Cui","year":"2015","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.cellsig.2025.111703_bb0785","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/abbs\/gmaa097","article-title":"BIX-01294-enhanced chemosensitivity in nasopharyngeal carcinoma depends on autophagy-induced pyroptosis [J]","volume":"52","author":"Li","year":"2020","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0790","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/noad222","article-title":"Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201 [J]","volume":"26","author":"Xin","year":"2024","journal-title":"Neuro-oncology"},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0795","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.stem.2016.02.004","article-title":"MLL1 inhibition reprograms epiblast stem cells to naive pluripotency [J]","volume":"18","author":"Zhang","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0800","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jb\/mvz007","article-title":"Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay [J]","volume":"166","author":"Murashima","year":"2019","journal-title":"J. Biochem."},{"issue":"8","key":"10.1016\/j.cellsig.2025.111703_bb0805","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","article-title":"PRMT inhibition induces a viral mimicry response in triple-negative breast cancer [J]","volume":"18","author":"Wu","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0810","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models [J]","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.cellsig.2025.111703_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108286","article-title":"EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumor effect in retinoblastoma [J]","volume":"202","author":"Liu","year":"2021","journal-title":"Exp. Eye Res."},{"issue":"18","key":"10.1016\/j.cellsig.2025.111703_bb0820","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.7150\/thno.59605","article-title":"PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression [J]","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0825","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/med.21399","article-title":"Aurora-a kinase: a potent oncogene and target for cancer therapy [J]","volume":"36","author":"Yan","year":"2016","journal-title":"Med. Res. Rev."},{"issue":"8","key":"10.1016\/j.cellsig.2025.111703_bb0830","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/jcp.25283","article-title":"New treatment of medullary and papillary human thyroid cancer: biological effects of hyaluronic acid hydrogel loaded with quercetin alone or in combination to an inhibitor of Aurora kinase [J]","volume":"231","author":"Quagliariello","year":"2016","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0835","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-22-0264","article-title":"SETDB1 modulates degradation of phosphorylated RB and anticancer efficacy of CDK4\/6 inhibitors [J]","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2025.111703_bb0840","first-page":"567","article-title":"Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+\/HER2- metastatic breast cancer: a focus on ribociclib [J]","volume":"9","author":"Edessa","year":"2017","journal-title":"Breast Cancer"},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0845","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1204","article-title":"The roles of E3 ubiquitin ligases in cancer progression and targeted therapy [J]","volume":"13","author":"Sampson","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.cellsig.2025.111703_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122409","article-title":"Skp2: a critical molecule for ubiquitination and its role in cancer [J]","volume":"338","author":"Feng","year":"2024","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0855","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13543784.2018.1417382","article-title":"Alisertib: a review of pharmacokinetics, efficacy, and toxicity in patients with hematologic malignancies and solid tumors [J]","volume":"27","author":"Liewer","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0860","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamaoncol.2022.7949","article-title":"Evaluation of alisertib alone or combined with Fulvestrant in patients with endocrine-resistant advanced breast Cancer: the phase 2 TBCRC041 randomized clinical trial [J]","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol."},{"issue":"21","key":"10.1016\/j.cellsig.2025.111703_bb0865","first-page":"2567","article-title":"Integrative analysis of senescence-related genes identifies robust prognostic clusters with distinct features in hepatocellular carcinoma [J]","volume":"137","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0870","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s10637-018-0625-6","article-title":"A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors [J]","volume":"36","author":"Carducci","year":"2018","journal-title":"Investig. New Drugs"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0875","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01943-22","article-title":"Inhibitors of one or more cellular Aurora kinases impair the replication of herpes simplex virus 1 and other DNA and RNA viruses with diverse genomes and life cycles [J]","volume":"11","author":"Ly","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.cellsig.2025.111703_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116155","article-title":"Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor [J]","volume":"223","author":"Zhang","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0885","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s13346-019-00668-5","article-title":"Augmentation of danusertib\u2019s anticancer activity against melanoma by blockage of autophagy [J]","volume":"10","author":"Shang","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0890","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of Ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and Perimenopausal patients with HR+\/HER2- advanced breast Cancer in MONALEESA-7: a phase III randomized clinical trial [J]","volume":"28","author":"Lu","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.cellsig.2025.111703_bb0895","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/13543784.2016.1169273","article-title":"Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia [J]","volume":"25","author":"Wiernik","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.cellsig.2025.111703_bb0900","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s12035-023-03609-z","article-title":"Flavopiridol suppresses cell proliferation and migration and induces apoptotic cell death by inhibiting oncogenic FOXM1 signaling in IDH wild-type and IDH-mutant GBM cells [J]","volume":"61","author":"Guler","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0905","first-page":"66","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer [J]","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0910","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomized, open-label, phase 3 trial [J]","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.cellsig.2025.111703_bb0915","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with Palbociclib and Fulvestrant in women with HR+\/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study [J]","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0920","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41420-023-01754-x","article-title":"The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma [J]","volume":"9","author":"Houles","year":"2023","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.cellsig.2025.111703_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer [J]","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.cellsig.2025.111703_bb0930","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","article-title":"CDK7 inhibitors as anticancer drugs [J]","volume":"39","author":"Sava","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"7","key":"10.1016\/j.cellsig.2025.111703_bb0935","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11071879","article-title":"MDM2 inhibition in the treatment of glioblastoma: from concept to clinical investigation [J]","volume":"11","author":"Pellot Ortiz","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0940","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s42003-023-05166-6","article-title":"Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells [J]","volume":"6","author":"Zhou","year":"2023","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.cellsig.2025.111703_bb0945","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.7150\/ijbs.69454","article-title":"The lncRNA BDNF-AS\/WDR5\/FBXW7 axis mediates ferroptosis in gastric cancer peritoneal metastasis by regulating VDAC3 ubiquitination [J]","volume":"18","author":"Huang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0950","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13046-023-02767-1","article-title":"FBXW7 in breast cancer: mechanism of action and therapeutic potential [J]","volume":"42","author":"Chen","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.cellsig.2025.111703_bb0955","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113460","article-title":"Importance of Cullin4 ubiquitin ligase in malignant pleural mesothelioma [J]","volume":"12","author":"Meerang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cellsig.2025.111703_bb0960","doi-asserted-by":"crossref","unstructured":"Wu K, Huynh K Q, Lu I, et al. Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potential [J]. Proc. Natl. Acad. Sci. USA, 2021, 118 8.","DOI":"10.1073\/pnas.2007328118"},{"issue":"19","key":"10.1016\/j.cellsig.2025.111703_bb0965","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1074\/jbc.RA117.000678","article-title":"The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators [J]","volume":"293","author":"Wai","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.cellsig.2025.111703_bb0970","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/s41587-022-01636-0","article-title":"Chem-map profiles drug binding to chromatin in cells [J]","volume":"41","author":"Yu","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0975","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy [J]","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cellsig.2025.111703_bb0980","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s42003-023-05395-9","article-title":"MUC1-C intersects chronic inflammation with epigenetic reprogramming by regulating the set1a compass complex in cancer progression [J]","volume":"6","author":"Bhattacharya","year":"2023","journal-title":"Commun. Biol."},{"issue":"3\u20134","key":"10.1016\/j.cellsig.2025.111703_bb0985","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1101\/gad.349803.122","article-title":"WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma [J]","volume":"37","author":"Mitchell","year":"2023","journal-title":"Genes Dev."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825001160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656825001160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:29:42Z","timestamp":1762316982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656825001160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":197,"alternative-id":["S0898656825001160"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.111703","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone modification inhibitors: An emerging frontier in thyroid Cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2025.111703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111703"}}